knowledge -WSS

knowledge

author：knowledge 2025-09-27 13:10:13 - browse：38913

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

The Danish pharmaceutical company Novo Nordisk has shepherded all kinds of medical innovation in the 110 years since it was founded. But the booming success of its diabetes and obesity drug is unlike anything executives have seen before.

The company’s mid-year operating profit jumped from 37.5 billion Danish kroner in 2022 to 48.9 billion Danish kroner this year — “probably the strongest growth in the history of the company,” Chief Financial Officer Karsten Munk Knudsen said during an August earnings call. The 30% growth rate came from sales of semaglutide, which Novo Nordisk sells for diabetes under the name Ozempic and for obesity as Wegovy.

With its new blockbuster drug in hand, Novo Nordisk is valued higher than the entire economy of Denmark, where it’s based.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Alabama frozen embryo ruling has major implications for IVF clinics

WSS

New documents shed light on MD Anderson Cancer Institute feud

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

Emergency medicine has repudiated 'excited delirium.' Now what?

Traditional Chinese medicine benefits explored in new JAMA study

Community Health Systems hospitals under DOJ investigation

Antivenom research: Lessons from HIV applied in search for universal antidote

hotspot

knowledge

hotspot

Medicare proposal to cover medical devices draws a mixed reaction

First Opinion Podcast: How to protect health care in times of war

BioMarin wins approval for gene therapy to treat hemophilia A

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Cassava reveals details — and problems — with Alzheimer's study

Drug repurposing or repositioning? The language matters

Readout Newsletter: What happened with Sarepta's Duchenne data

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Cassava reveals details — and problems — with Alzheimer's study

leisure time

In utero gene editing: an explainer

Antivenom research: Lessons from HIV applied in search for universal antidote

First Opinion Podcast: How to protect health care in times of war

Testing for cancer recurrence creates a new limbo for patients

First Opinion Podcast: How to protect health care in times of war

A new nitrogen execution bill also undermines medical licensing

entertainment

knowledge

leisure time

leisure time